News

The novel, fully human, antagonist antibody targets the CD40 antigen which is associated with multiple myeloma. The single-agent, open-label phase I study of CHIR-12.12 will recruit up to

The Committee for Orphan Medical Products, a division of the European Medicines Agency (EMEA), recommended the designation for Tilarginine Acetate Injection (TAI) for the treatment of cardiogenic shock.

The companies believe their diagnostic tests to be completely novel. They believe the tests could enable the detection of cancer from a simple blood sample and at a

This designation indicates that the appropriate information has been provided for the review of the new drug application. The company believes that this review will be completed within

The company has also entered a cooperative R&D agreement with the National Cancer Institute, a collaborator in the development of the RTA 401 compound. RTA 401 is the

The safety and efficacy study will evaluate Merrimack’s lead product MM-093, a recombinant version of human alpha-fetoprotein (AFP). The placebo controlled study will enroll approximately 30 adult outpatients

Benign prostatic hyperplasia afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with

In this trial, taking place in Thailand, patients are treated for three days with DB289, as a single therapy or in combination with the drug artesunate. Trial patients

The strategic agreement between the partners covers development of both pandemic and interpandemic (seasonal) influenza vaccines using Crucell’s proprietary PERC6 cell line technology. Clinical trials for Sanofi /